Upcoming Earnings: Q2 '26
Estimated EPS
-$0.17
Estimated Rev
$0M
$ALLO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.18 up 35.71% YoY • Allogene Therapeutics expects its $266.9M in cash, cash equivalents, and investments as of March 31, 2026, plus $187.9M from the April 2026 Public Offering, will fund operations into Q1 2029.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.17 | -- | -- | N/A |
Q1 '26 | -$0.19 | -$0.18 | 5.32% | BEAT |
Q4 '25 | -$0.23 | -$0.17 | 24.62% | BEAT |
Q3 '25 | -$0.22 | -$0.19 | 13.95% | BEAT |
Q2 '25 | -$0.27 | -$0.23 | 14.07% | BEAT |